title: Treatment patterns of FIGO Stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy.
abstract: OBJECTIVE
  The treatment of FIGO stage IB2 cervical cancer is controversial. Our aim was to assess treatment patterns, outcomes, and complications in patients with stage IB2 cervical cancer.
  
  
  METHODS
  A retrospective study of patients with stage IB2 cervical carcinoma at a single institution between January 1982 and September 2006 was performed. To adequately control treatment variables, we only included patients who underwent their entire treatment at our institution. Toxicity was assessed using NCI Common Toxicity Criteria (CTC).
  
  
  RESULTS
  We identified 82 patients, of whom 47 met the strict inclusion criteria. Of these, 27 patients (57%) underwent primary radical hysterectomy (RH) and 20 (43%) were treated with definitive radiation/chemoradiation therapy (RT/CRT). Patients selected for RT/CRT had a higher American Society of Anesthesiologist (ASA) score than those selected for surgery (P=0.037). The 3-year progression free survival rate was 52% for the RH group and 55% for the RT/CRT group (P=0.977). The 3-year overall survival rates were 72% and 55%, respectively (P=0.161). Overall, 52% of patients in the RH group received postoperative radiation therapy as part of their adjuvant treatment. CTC grade 3, 4, and 5 complications affected 5 patients (19%) in the RH group and 3 (15%) in the RT/CRT group.
  
  
  CONCLUSIONS
  Both RH and definitive RT/CRT are adequate management strategies for patients with FIGO stage IB2 cervical cancer. However, there was a subset of patients in whom RH as monotherapy was appropriate. Further studies are needed to evaluate the role of new preoperative models that will accurately identify these patients.
authors.affiliation: Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
authors.forename: Oliver
authors.initials: O
authors.lastname: Zivanovic
authors.forename: Kaled M
authors.initials: KM
authors.lastname: Alektiar
authors.forename: Yukio
authors.initials: Y
authors.lastname: Sonoda
authors.forename: Qin
authors.initials: Q
authors.lastname: Zhou
authors.forename: Alexia
authors.initials: A
authors.lastname: Iasonos
authors.forename: William P
authors.initials: WP
authors.lastname: Tew
authors.forename: John P
authors.initials: JP
authors.lastname: Diaz
authors.forename: Dennis S
authors.initials: DS
authors.lastname: Chi
authors.forename: Richard R
authors.initials: RR
authors.lastname: Barakat
authors.forename: Nadeem R
authors.initials: NR
authors.lastname: Abu-Rustum
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D055815:Young Adult
references.citation: Obstet Gynecol. 1974 Aug;44(2):265-72
references.pmid: 4417035
references.citation: Gynecol Oncol. 1989 Dec;35(3):314-20
references.pmid: 2599466
references.citation: Int J Gynecol Cancer. 2006 May-Jun;16(3):1147-51
references.pmid: 16803498
references.citation: J Reprod Med. 2005 Jul;50(7):486-90
references.pmid: 16130844
references.citation: Lancet. 1997 Aug 23;350(9077):535-40
references.pmid: 9284774
references.citation: Gynecol Oncol. 1999 May;73(2):177-83
references.pmid: 10329031
references.citation: Cancer. 1989 Jun 1;63(11):2220-3
references.pmid: 2720571
references.citation: Int J Radiat Oncol Biol Phys. 1994 Apr 30;29(1):9-16
references.pmid: 8175451
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: Surg Gynecol Obstet. 1980 Apr;150(4):529-31
references.pmid: 7361240
references.citation: Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):605-13
references.pmid: 9486610
references.citation: Obstet Gynecol. 1975 Nov;46(5):507-10
references.pmid: 1196552
references.citation: Am J Obstet Gynecol. 1976 Dec 1;126(7):785-98
references.pmid: 998673
references.citation: Gynecol Oncol. 1983 Feb;15(1):42-7
references.pmid: 6401639
references.citation: J Clin Oncol. 2000 Apr;18(8):1740-7
references.pmid: 10764435
references.citation: J Clin Oncol. 2000 Apr;18(8):1606-13
references.pmid: 10764420
references.citation: N Engl J Med. 1999 Apr 15;340(15):1154-61
references.pmid: 10202166
references.citation: Cancer. 1991 Jul 15;68(2):272-7
references.pmid: 2070325
references.citation: Cancer. 1992 Jun 1;69(11):2796-806
references.pmid: 1571911
references.citation: Gynecol Oncol. 1996 Apr;61(1):3-10
references.pmid: 8626113
references.citation: Gynecol Oncol. 2003 Jun;89(3):343-53
references.pmid: 12798694
references.citation: Int J Cancer. 2001 Oct 15;94(2):153-6
references.pmid: 11668491
references.citation: Gynecol Oncol. 1989 Apr;33(1):34-9
references.pmid: 2703164
references.citation: Int J Gynecol Cancer. 2007 Jan-Feb;17(1):132-6
references.pmid: 17291243
references.citation: Gynecol Oncol. 2007 Dec;107(3):532-40
references.pmid: 17900674
references.citation: J Am Coll Surg. 1996 Oct;183(4):393-400
references.pmid: 8843270